Skin Longevity Evidence Map

Note: Vascular complications (occlusion, blindness) are rare and depend on operator training and access to hyaluronidase emergency protocol.

Note: Not FDA-approved as an HA dermal filler indication in the United States; CE Class III and TİTCK-registered medical device. Patient consent must clarify this regulatory distinction.

Note: Cosmetic use is off-label in the United States. Preparation protocols (platelet concentration, activation method, volume) vary between providers; comparisons should be made with caution.

Note: Protocols are heterogeneous; "mesotherapy" is a delivery technique rather than a single approved product. Each component carries its own regulatory status.

Note: Only the Ultherapy brand carries the cited FDA 510(k) clearances; other devices marketed as "HIFU" may follow different regulatory pathways. Verify device-specific clearance with your provider.

Note: Device selection (CO2 vs Er:YAG vs non-ablative) depends on Fitzpatrick skin type, downtime tolerance, and target indication.

Note: Tretinoin is contraindicated in pregnancy and breastfeeding. Initial irritation (retinoid dermatitis) is common and managed with lower concentration and nighttime application.

Note: Stabilization (pH < 3.5, anhydrous formulation, or ascorbyl glucoside derivative) is critical for efficacy; oxidized product shows a yellow-brown color change.

Note: Higher-strength peels (e.g., >30% glycolic, 20-30% salicylic) should be performed in-office; risk of post-inflammatory hyperpigmentation is elevated in Fitzpatrick IV-VI skin.

Note: Lifestyle recommendations fall outside regulatory authority scope but form the cornerstone of the Skin Longevity approach. Smoking, alcohol, chronic UV exposure, and sleep debt are the dominant modifiable factors in skin aging.